Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 520

1.

Lung cancer risks, beliefs and healthcare access among the underprivileged.

Morère JF, Viguier J, Touboul C, Pivot X, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jul;24 New insights on cancer screening from the EDIFICE 3 survey:S82-S86.

PMID:
26334225
2.

Social stratification, risk factor prevalence and cancer screening attendance.

Eisinger F, Viguier J, Touboul C, Coscas Y, Pivot X, Blay JY, Lhomel C, Morère JF.

Eur J Cancer Prev. 2015 Jul;24 New insights on cancer screening from the EDIFICE 3 survey:S77-S81.

PMID:
26334224
3.

Breast cancer screening controversy: too much or not enough?

Pivot X, Viguier J, Touboul C, Morère JF, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jul;24 New insights on cancer screening from the EDIFICE 3 survey:S73-S76.

PMID:
26334223
4.

Cancer screening in France: third edition of the EDIFICE survey.

Viguier J, Morère JF, Touboul C, Coscas Y, Blay JY, Lhomel C, Pivot X, Eisinger F.

Eur J Cancer Prev. 2015 Jul;24 New insights on cancer screening from the EDIFICE 3 survey:S68-S72.

PMID:
26334222
5.

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.

Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Coquard IR, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY.

Oncotarget. 2015 Jul 21. [Epub ahead of print]

6.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J.

N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.

PMID:
26287849
7.

The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.

Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK.

Gastric Cancer. 2015 Aug 15. [Epub ahead of print]

PMID:
26276366
8.

The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.

Barrios CH, Blackstein ME, Blay JY, Casali PG, Chacon M, Gu J, Kang YK, Nishida T, Purkayastha D, Woodman RC, Reichardt P.

Eur J Cancer. 2015 Aug 3. pii: S0959-8049(15)00689-9. doi: 10.1016/j.ejca.2015.07.010. [Epub ahead of print]

9.

Small cell carcinoma of the ovary, hypercalcemic type/ ovarian malignant rhabdoid tumor: report of a bilateral case in a teenager associated with SMARCA4 germline mutation.

Lavrut PM, LE Loarer F, Normand C, Grosos C, Dubois R, Buenerd A, Conter C, Dijoud F, Blay JY, Collardeau-Frachon S.

Pediatr Dev Pathol. 2015 Jul 31. [Epub ahead of print]

PMID:
26230154
10.

Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.

Ray-Coquard IL, Domont J, Tresch-Bruneel E, Bompas E, Cassier PA, Mir O, Piperno-Neumann S, Italiano A, Chevreau C, Cupissol D, Bertucci F, Bay JO, Collard O, Saada-Bouzid E, Isambert N, Delcambre C, Clisant S, Le Cesne A, Blay JY, Penel N.

J Clin Oncol. 2015 Sep 1;33(25):2797-802. doi: 10.1200/JCO.2015.60.8505. Epub 2015 Jul 27.

PMID:
26215950
11.

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)†.

Bompas E, Le Cesne A, Tresch-Bruneel E, Lebellec L, Laurence V, Collard O, Saada-Bouzid E, Isambert N, Blay JY, Amela EY, Salas S, Chevreau C, Bertucci F, Italiano A, Clisant S, Penel N.

Ann Oncol. 2015 Jul 22. pii: mdv300. [Epub ahead of print]

PMID:
26202596
12.

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D.

Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.

PMID:
26179200
13.

Nilotinib versus imatinib for GIST - Authors' reply.

Blay JY, Hurh E, Green S, Novick S.

Lancet Oncol. 2015 Jul;16(7):e311-2. doi: 10.1016/S1470-2045(15)00016-9. No abstract available.

PMID:
26149878
14.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

PMID:
26137416
15.

[Quinze questions importantes à se poser en oncologie en 2015].

Blay JY, Tredan O, Ray-Coquard I, Rivoire M, Mehlen P, Puisieux A, Bachelot T.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S22-6. doi: 10.1016/S0007-4551(15)31214-5. Review. French.

PMID:
26118872
16.

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martín-Broto J, Nishida T, Reichardt P, Schöffski P, Trent JC.

Oncologist. 2015 Jul;20(7):823-30. doi: 10.1634/theoncologist.2014-0471. Epub 2015 Jun 12. Review.

PMID:
26070915
17.
18.

Lung cancer risks, beliefs and healthcare access among the underprivileged.

Morère JF, Viguier J, Touboul C, Pivot X, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S82-6. doi: 10.1097/CEJ.0000000000000143.

PMID:
26016793
19.

Social stratification, risk factor prevalence and cancer screening attendance.

Eisinger F, Viguier J, Touboul C, Coscas Y, Pivot X, Blay JY, Lhomel C, Morère JF.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S77-81. doi: 10.1097/CEJ.0000000000000144.

PMID:
26016792
20.

Breast cancer screening controversy: too much or not enough?

Pivot X, Viguier J, Touboul C, Morère JF, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S73-6. doi: 10.1097/CEJ.0000000000000145.

PMID:
26016791
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk